Table 1.
Demographic data and clinical variables of the patient population
| Stable (14) | BOS (6) | |
|---|---|---|
| Age (median, IQR) | 59.5 (43.5, 63.5) | 56.0 (52.5, 64.5) |
| Gender (female %) | 3 (21%) | 2 (33%) |
| Initial disease: | ||
| COPD | 3 | 2 |
| IPF | 9 | 2 |
| Other | 2 | 2 |
| SLTx | 7 | 4 |
| BLTx | 7 | 2 |
| Follow up time (median, IQR) | 20(11, 27) | -- |
| Time to BOS (median, IQR) | -- | 12 (11,16) |
| Immunosuppression: | ||
| Tac/Aza/Pred | 8 | 1 |
| Tac/MMF/Pred | 4 | 1 |
| Tac/Sir/Pred | 2 | 3 |
| CsA/Sir/Pred | 1 | |
| Average number of BAL specimens (per lung transplant recipient) | 3.1 ± 1.1 | 3.2 ± 1.2 |
| Mean time from transplant to BAL specimens (months) | 7.3 ± 6.9 | 7.9 ± 4.6 |
| # patients with AR | 10 (71%) | 5 (83%) |
| # episodes of AR | 13 | 8 |
| Grade of AR: | ||
| Grade A1 | 6 | 5 |
| Grade A2 or higher | 4 | 2 |
| Grade B | 3 | 1 |
COPD, chronic obstructive pulmonary disease; IPF, idiopathic pulmonary fibrosis; SLTx, single lung transplant; BLTx, bilateral lung transplant; BOS, Bronchiolitis Obliterans Syndrome; Tac, tacrolimus; Aza, azathioprine; Pred, prednisone; MMF, mycophenolate mofetil; Sir, sirolimus; CsA, cyclosporine A; BAL, bronchoalveolar lavage; AR, acute rejection